BPC-157 vs KLOW Blend
BPC-157 (Synthetic pentadecapeptide) and KLOW Blend (Multi-component research blend) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | BPC-157 | KLOW Blend |
|---|---|---|
| Compound class | Synthetic pentadecapeptide | Multi-component research blend |
| Research category | Healing & Recovery | Healing & Recovery |
| Length (amino acids) | 15 amino acids | Not documented |
| Molecular weight | 1419.5 Da | Not documented |
| Half-life | <30 minutes (elimination, reported in rats/dogs) | Not documented |
| Origin | BPC-157 is a synthetic peptide whose sequence corresponds to a partial fragment of human body protection compound (BPC), a protein reported to be present in gastric juice. It does not occur naturally as an isolated peptide and is produced synthetically for research. | KLOW is a marketed multi-component research blend. It is typically described as combining GHK-Cu (copper tripeptide), KPV (an alpha-MSH fragment), and a BPC-157 / TB-500 combination. Exact composition can vary by supplier and it is not a naturally occurring substance. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How BPC-157 works
In animal and in-vitro studies, BPC-157 has been associated with promotion of angiogenesis and modulation of growth-factor signaling pathways, including effects reported on the VEGFR2 pathway and nitric oxide systems. Researchers have also described interactions with the FAK-paxillin pathway and effects on fibroblast and tendon-cell migration. These mechanisms are characterized primarily in rodent models and cell culture and have not been established in controlled human trials.
How KLOW Blend works
As a blend, KLOW combines the documented properties of its components: GHK-Cu's copper-delivery and tissue-remodeling signaling, KPV's melanocortin-pathway anti-inflammatory activity, BPC-157's angiogenesis and growth-factor-related repair signaling, and TB-500's actin-regulation and cell-migration effects. These properties come from separate preclinical and cosmetic research; the combined formulation is not independently validated in controlled human trials.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
BPC-157
KLOW Blend
What sets each apart
BPC-157
Unlike copper-binding cosmetic tripeptides or the actin-modulating TB-500, BPC-157 is a longer synthetic peptide studied primarily for connective-tissue and gastrointestinal repair endpoints in animals.
KLOW Blend
KLOW is a broader combination than two-component blends, pairing a copper cosmetic tripeptide and an anti-inflammatory MSH fragment with repair-focused peptides.
Documented together as a research blend
Cross-referenced for research context — not a usage or combination recommendation.
Frequently asked questions
What is BPC-157 and what class of peptide is it?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids derived from a partial sequence of a protein found in human gastric juice. It is studied in the research literature as a cytoprotective and tissue-repair agent, not as an approved drug. It has no established endogenous receptor and its mechanisms are still under active investigation.
What is BPC-157 studied for in the research literature?
In animal models, BPC-157 has been researched in the context of tendon, ligament, muscle, and bone healing, gastrointestinal mucosal protection, and angiogenesis. Much of the work implicates nitric oxide pathways and upregulation of growth-factor and angiogenic signaling. To date these findings are almost entirely preclinical, and no human clinical efficacy has been established.
Why is BPC-157's short half-life not reflected in dosing frequency?
Pharmacokinetic work in rats and dogs reports an elimination half-life under about 30 minutes, yet most rodent studies use once-daily dosing. This is often described as a PK/PD disconnect: the downstream biological effects the peptide triggers persist well beyond the peptide's own residence time. Researchers therefore design protocols around effect duration rather than plasma half-life.
What is the KLOW blend and what does the name mean?
KLOW is a four-component research blend most commonly composed of KPV, GHK-Cu, BPC-157, and TB-500. The name is generally described as KPV added to the GLOW blend, where GLOW is GHK-Cu + BPC-157 + TB-500. Exact composition and ratios vary by supplier, so the vial's COA is the authoritative source.
What is each component in KLOW contributing?
In research terms, GHK-Cu (copper tripeptide) is studied for gene-expression modulation and tissue remodeling, BPC-157 for angiogenic and nitric-oxide signaling, TB-500 for actin dynamics and cell migration, and KPV for anti-inflammatory NF-kB modulation. The blend is used to study combined tissue-repair and inflammation pathways rather than any single target. All such effects are preclinical.
What is a typical KLOW vial composition?
One commonly cited configuration is an 80 mg vial containing roughly 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV. Other vendors use different totals and ratios, so this should be verified against the specific product's certificate of analysis rather than assumed.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.